Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Comment: Who to refer?
Neil Cox
Let me start by saying that those of you who read the title of this item and think that all your problems are over will be disappointed. This is not an editorial listing conditions that ought to be seen by dermatologists (although maybe that is something we should consider for a future article); it is more of a comment on a trend that I have observed over several years.
Dermatology in practice
2001;
9
(1): 3–3
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
Eli Lilly/Almirall announce long-term results for IL-13 inhibitor Ebglyss in atopic dermatitis
LEO Pharma’s Anzupgo cream granted EC approval in chronic hand eczema
UCB announces two-year data for Bimzelx in hidradenitis suppurativa
Sanofi/Regeneron’s Dupixent shows promise in phase 3 chronic spontaneous urticaria study
Merck announces ten-year data for anti-PD-1 therapy Keytruda in melanoma
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy